Preclinical pharmacokinetic evaluation of a new formulation of a bifendate solid dispersion using a supercritical fluid chromatography–tandem mass spectrometry method

Abstract

Listen

Translate article

In order to evaluate the pharmacokinetic characteristics of a new formulation of a bifendate solid dispersion in beagle dogs, a novel, sensitive and rapid supercritical fluid chromatography–tandem mass spectrometry (SFC–MS/MS) method was established and validated. Plasma samples were subjected to liquid–liquid extraction with ethyl acetate. Separation of bifendate and diazepam (internal standard, IS) was performed on an HSS C18 SB column (3×100mm, 1.8μm) with a mobile phase consisting of CO2 (≥99.99%) – methanol (95:5, v/v) at a flow rate of 2mL/min and the compensation solvent was methanol with 2% formic acid at a flow rate of 0.2mL/min. A tandem triple quadrupole mass spectrometer was operated in multiple reaction monitoring (MRM) mode with an electrospray ionization (ESI) source. Quantification of the ion transitions was at m/z 419.2→387.0 and 284.5→193.2 for bifendate and IS, respectively. The method was sensitive with a lower limit of quantification (LLOQ) of 0.5ng/mL and linear over the concentration range 0.5–250ng/mL. All the validation data, such as precision, accuracy, extraction recovery and matrix effect, were all within acceptable criteria. The method has been successfully applied to a pharmacokinetic study of bifendate in beagle dogs after oral administration of a bifendate solid dispersion.